Zibotentan Can Be Co‐administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug–Drug Interaction Study

Author:

Mercier Anne‐Kristina1ORCID,Kois Abigail K.2,Karsanji Deeyen3ORCID,Baldry Richard3ORCID,Birve Filip4ORCID,Hedwall Maria5,Molodetskyi Oleksandr6ORCID,Gillen Michael7

Affiliation:

1. Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D AstraZeneca Gothenburg Sweden

2. Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D AstraZeneca Gaithersburg Maryland USA

3. Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D AstraZeneca Cambridge UK

4. Biometrics, Late‐Stage Development, Cardiovascular, Renal and Metabolism, R&D AstraZeneca Gothenburg Sweden

5. Clinical, Late‐Stage Development, Cardiovascular, Renal and Metabolism, R&D AstraZeneca Gothenburg Sweden

6. Global Patient Safety BioPharmaceuticals, Chief Medical Office, R&D AstraZeneca Gothenburg Sweden

7. Creek Lane PK, LLC Waterford Virginia USA

Abstract

The endothelin A receptor antagonist zibotentan, combined with the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin, is being investigated for the treatment of chronic kidney disease with high proteinuria. To allow women of childbearing potential access to this treatment, highly effective contraception is required and drug interactions compromising contraception reliability must be avoided. This study investigated the risk of pharmacokinetic (PK) interaction between zibotentan and the contraceptives ethinyl estradiol and levonorgestrel. A single‐sequence, within‐participant comparison study was conducted in 24 healthy women of non‐childbearing potential, comparing the PK of ethinyl estradiol/levonorgestrel alone and with zibotentan. Single oral doses of 0.06 mg ethinyl estradiol/0.3 mg levonorgestrel were administered on Days 1 and 15; zibotentan 10 mg was dosed orally, once‐daily through Days 6–19. PK profiles were determined and ethinyl estradiol/levonorgestrel PK was compared between Day 1 and 15 based on geometric least‐squares mean ratios of PK parameters, including maximum observed concentration (Cmax) and area under the plasma concentration–time curve from zero to infinity (AUCinf). Co‐administration with zibotentan did not affect ethinyl estradiol PK (geometric mean ratio [90% confidence interval] Cmax 1.05 [0.99–1.11], AUCinf 1.00 [0.96–1.05]), while a weak interaction (increased exposure) was observed for levonorgestrel (Cmax 1.12 [1.02–1.23], AUCinf 1.30 [1.21–1.39]), which was regarded as without clinical relevance. Plasma exposure of ethinyl estradiol/levonorgestrel was not reduced by multiple‐dose zibotentan. In conclusion, contraception containing ethinyl estradiol/levonorgestrel is regarded possible under zibotentan‐containing treatments. This expands choices for women of childbearing potential, supporting diversity in the ZENITH High Proteinuria trial.

Publisher

Wiley

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3